<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1182">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145764</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00301337</org_study_id>
    <secondary_id>UH3DA048734</secondary_id>
    <nct_id>NCT05145764</nct_id>
  </id_info>
  <brief_title>Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl</brief_title>
  <official_title>Suvorexant as an Adjunct to Buprenorphine Induction and Maintenance in Persons Who Use Fentanyl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid&#xD;
      use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day&#xD;
      residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone,&#xD;
      followed by a 3-week outpatient phase wherein participants are maintained on sublingual&#xD;
      buprenorphine/naloxone and transitioned to extended-release buprenorphine).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll persons with opioid use disorder (N=120) who have recent fentanyl&#xD;
      exposure (as assessed via urinalysis testing). Participants will be randomized to receive&#xD;
      suvorexant or placebo for the duration of the study enrollment, which will serve as the&#xD;
      between-groups experimental comparison. The study will consist of a brief (5 day) residential&#xD;
      phase and 3-week outpatient phase. During the residential phase, all participants will be&#xD;
      briefly maintained on morphine prior to induction onto sublingual (SL) buprenorphine (using&#xD;
      either the buprenorphine or buprenorphine/naloxone product). At the end of the 5-day&#xD;
      residential period, participants will be discharged to complete the ~3-week outpatient phase.&#xD;
      During the outpatient period all participants will be maintained on SL buprenorphine/naloxone&#xD;
      and continue to receive suvorexant or placebo, and at the end of the study participants will&#xD;
      receive an injection of XR-buprenorphine (Sublocade). All buprenorphine procedures will be&#xD;
      open label and will follow standard-of-care practices. Study medication during the outpatient&#xD;
      period will be managed using an automated pill dispenser. Data collection will consist of&#xD;
      forehead-based EEG monitoring, wrist-worn actigraphy/photoplethysmography, and questionnaires&#xD;
      delivered during study visits or via cell-phone based ecological momentary assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>3 nights during the initial residential phase and 1 night at the end of outpatient treatment</time_frame>
    <description>Duration of nightly total sleep time in minutes, as measured by electroencephalography (EEG) and supplemented by actigraphy/photoplethysmography (e.g., if EEG malfunctions).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Buprenorphine compliance as assessed by the number of study days complying with buprenorphine treatment</measure>
    <time_frame>25 days across residential and outpatient treatment</time_frame>
    <description>Buprenorphine compliance will be assessed by the number of study days complying with buprenorphine treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Suvorexant</condition>
  <condition>Placebo</condition>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>Suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nightly dosing of suvorexant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nightly dosing of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Encapsulated suvorexant (matched for color, weight, and size)</description>
    <arm_group_label>Suvorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Encapsulated placebo (matched for color, weight, and size)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18-65&#xD;
&#xD;
          -  Meets DSM-5 criteria for opioid use disorder (OUD) with evidence of physical&#xD;
             dependence on opioids&#xD;
&#xD;
          -  Provides a urine sample that tests positive for fentanyl and/or fentanyl analogues&#xD;
&#xD;
          -  Interest in being maintained on buprenorphine for OUD&#xD;
&#xD;
          -  Plans to reside in current area for study period&#xD;
&#xD;
          -  Achieving a study maintenance dose of &gt;=8mg sublingual buprenorphine/naloxone&#xD;
&#xD;
          -  Willing to comply with study protocol&#xD;
&#xD;
          -  Have no clinically significant chronic medical or surgical disorders or conditions&#xD;
             that are judged by the investigators to prevent participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medically contraindicated for buprenorphine, extended-release (XR)-buprenorphine&#xD;
             (Sublocade), or suvorexant (as per medication labels)&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Severe Diagnostic and Statistical Manual (DSM)-5 alcohol, benzodiazepine, or stimulant&#xD;
             use disorder or evidence of alcohol/benzodiazepine physical dependence&#xD;
&#xD;
          -  Have a known allergy to the study medications&#xD;
&#xD;
          -  Past 30-day prescribed use of suvorexant for the indication of insomnia&#xD;
&#xD;
          -  Current benzodiazepine or other prescribed medication for the indication of insomnia&#xD;
&#xD;
          -  Urine sample testing positive for benzodiazepine at screening and admission to&#xD;
             residential treatment&#xD;
&#xD;
          -  Current narcolepsy, restless leg syndrome or sleep paralysis&#xD;
&#xD;
          -  High risk for current sleep apnea&#xD;
&#xD;
          -  Current (past 30-day) suicidal behaviors&#xD;
&#xD;
          -  Severe hepatic or renal impairment&#xD;
&#xD;
               -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;3x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin &gt;2x ULN&#xD;
&#xD;
               -  Creatinine &gt;1.5x ULN&#xD;
&#xD;
          -  Past year clinically-significant psychiatric condition judged to interfere with study&#xD;
             participation&#xD;
&#xD;
          -  Lack of access to stable housing (necessary for electronic pill dispenser charging)&#xD;
&#xD;
          -  Have circumstances that would interfere with study participation (e.g., impending&#xD;
             jail)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S Huhn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew S Huhn, Ph.D.</last_name>
    <phone>410-550-1971</phone>
    <email>ahuhn1@jhu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly E Dunn, Ph.D.</last_name>
    <phone>410-550-2254</phone>
    <email>kdunn9@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrew S Huhn, Ph.D.</last_name>
      <phone>410-550-1971</phone>
      <email>ahuhn1@jhu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid use disorder</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Suvorexant</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

